Back to top
more

Actinium Pharmaceuticals (ATNM)

(Delayed Data from AMEX)

$1.60 USD

1.60
73,645

-0.02 (-1.23%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $1.60 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (83 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $9.18, moving -1.71% from the previous trading session.

Zacks Equity Research

Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ATNM) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Is a Surprise Coming for Actinium Pharmaceuticals (ATNM) This Earnings Season?

by Zacks Equity Research

Actinium Pharmaceuticals (ATNM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

United Therapeutics Announces FDA Acceptance of Tyvaso sNDA

by Zacks Equity Research

United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Zacks Equity Research

Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (ATNM) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Actinium Pharmaceuticals (ATNM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues In Line

by Zacks Equity Research

Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $0.59, marking a -1.67% move from the previous day.

Zacks Equity Research

Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $0.59, marking a -0.78% move from the previous day.

Zacks Equity Research

Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ATNM) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Actinium Pharmaceuticals (ATNM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Implied Volatility Surging for Actinium Pharmaceuticals (ATNM) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Actinium Pharmaceuticals (ATNM) stock based on the movements in the options market lately.

Zacks Equity Research

Actinium Pharmaceuticals, Inc. (ATNM) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Actinium Pharmaceuticals, Inc. (ATNM).

Zacks Equity Research

Actinium Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Actinium Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (ATNM) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio

Zacks Equity Research

4 Small Drug Stocks Worth Betting on Amid Coronavirus Woes

by Zacks Equity Research

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

Zacks Equity Research

Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ATNM) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Jazz's Aggressive Lung Cancer Drug Zepzelca Gets FDA Approval

by Zacks Equity Research

FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.

Zacks Equity Research

Is the Options Market Predicting a Spike in Actinium Pharmaceuticals (ATNM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Actinium Pharmaceuticals (ATNM) stock based on the movements in the options market lately.

Zacks Equity Research

How Actinium Pharmaceuticals (ATNM) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Actinium Pharmaceuticals (ATNM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7%

by Zacks Equity Research

Actinium Pharmaceuticals (ATNM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Equity Research

Actinium Treats First Patient in AML Study on Actimab-A Combo

by Zacks Equity Research

Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.

Zacks Equity Research

Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.